Overview

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II multicenter, non-comparative, open label study in older previously untreated Chronic Lymphocytic Leukaemia patients, requiring therapy, aimed at defining the efficacy profile (ORR, CRR and TTP) of pentostatin and cyclophosphamide given in combination with Ofatumumab (PCO).
Phase:
Phase 2
Details
Lead Sponsor:
Niguarda Hospital
Collaborators:
GlaxoSmithKline
Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer
Regione Lombardia
Treatments:
Antibodies, Monoclonal
Cyclophosphamide
Ofatumumab
Pentostatin